Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Inside Precision Medicine. Innehållet i podden är skapat av Inside Precision Medicine och inte av, eller tillsammans med, Poddtoppen.